What is Wedbush’s Estimate for RARE Q1 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Wedbush cut their Q1 2025 earnings estimates for Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of ($1.09) for the quarter, down from their previous estimate of ($1.06). Wedbush has a “Neutral” rating and a $48.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.81) EPS, FY2028 earnings at $1.91 EPS and FY2029 earnings at $3.20 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Piper Sandler reduced their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday, March 17th. JPMorgan Chase & Co. raised their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Finally, Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $92.79.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $35.69 on Friday. The firm has a fifty day moving average price of $38.57 and a 200 day moving average price of $44.40. Ultragenyx Pharmaceutical has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The firm has a market cap of $3.35 billion, a PE ratio of -5.63 and a beta of 0.61.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 323 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth about $35,000. Human Investing LLC bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth about $42,000. Finally, Van ECK Associates Corp increased its position in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 273 shares during the period. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares of the company’s stock, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Theodore Alan Huizenga sold 967 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock valued at $5,256,268 in the last quarter. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.